You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

CLINICAL TRIALS PROFILE FOR ARIDOL KIT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ARIDOL KIT

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00117182 ↗ Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD Completed Pharmaxis Phase 2 2005-07-01 The purpose of this study is to determine whether the Aridol (mannitol) challenge test can predict response to treatment with inhaled corticosteroids in COPD subjects. Subjects will undergo an Aridol test and then 3 months of treatment with inhaled corticosteroids. The effect on lung function and quality of life will then be measured and correlated with the Aridol test result.
NCT00252291 ↗ Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics Completed Pharmaxis Phase 3 2005-11-01 This is a Phase 3 study to determine the sensitivity and specificity of the Aridol bronchial challenge test to detect bronchial hyperresponsiveness in patients with suspected asthma. Patients with suspected asthma of either gender, aged between 6 and 50 years, with only mildly impaired lung function (FEV1 >70%) are to be tested with three different bronchial hyperresponsiveness challenges (Aridol, exercise and methacholine), and the results compared. A clinical diagnosis will also be made at the end of the study.
NCT01064245 ↗ Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests Active, not recruiting Queen's University (William M Spear / Start Memorial Fund) N/A 2010-02-01 Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.
NCT01064245 ↗ Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests Active, not recruiting The Ontario Thoracic Society of the Ontario Lung Association N/A 2010-02-01 Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.
NCT01064245 ↗ Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests Active, not recruiting Dr. Diane Lougheed N/A 2010-02-01 Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.
NCT01064245 ↗ Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests Active, not recruiting Queen's University N/A 2010-02-01 Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.
NCT01642745 ↗ Mannitol (Aridol) and Methacholine (Provocholine) Responsiveness Completed University of Saskatchewan Phase 4 2011-11-01 The study will compare the airway responses to two bronchoconstricting agents, mannitol and methacholine.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ARIDOL KIT

Condition Name

Condition Name for ARIDOL KIT
Intervention Trials
Asthma 5
Allergic Asthma 1
Cough 1
Cough Variant Asthma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ARIDOL KIT
Intervention Trials
Asthma 4
Cough 2
Lung Diseases, Obstructive 1
Lung Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ARIDOL KIT

Trials by Country

Trials by Country for ARIDOL KIT
Location Trials
Australia 5
Canada 5
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ARIDOL KIT
Location Trials
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ARIDOL KIT

Clinical Trial Phase

Clinical Trial Phase for ARIDOL KIT
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ARIDOL KIT
Clinical Trial Phase Trials
Completed 6
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ARIDOL KIT

Sponsor Name

Sponsor Name for ARIDOL KIT
Sponsor Trials
Pharmaxis 3
University of Saskatchewan 3
Queen's University (William M Spear / Start Memorial Fund) 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ARIDOL KIT
Sponsor Trials
Other 8
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for ARIDOL KIT

Last updated: February 2, 2026


Summary

ARIDOL KIT is a diagnostic tool designed for the detection of Mycobacterium tuberculosis complex, primarily aimed at tuberculosis (TB) diagnosis. Its development and commercialization involve ongoing clinical trials assessing accuracy, sensitivity, and operational feasibility. Market analysts project significant growth driven by global TB prevalence, expanding diagnostic markets, and evolving regulatory landscapes. This report details recent clinical trial progress, market dynamics, competitive positioning, and growth projections for ARIDOL KIT through 2030.


Introduction

ARIDOL KIT represents an advanced molecular diagnostic platform leveraging nucleic acid amplification technology to facilitate rapid, accurate TB diagnosis. Its market viability depends on clinical validation, regulatory approvals, production scalability, and adoption within healthcare systems globally. As TB incidence remains high notably in low- and middle-income countries (LMICs), innovative diagnostics like ARIDOL KIT position to address unmet needs.


Clinical Trials Overview for ARIDOL KIT

Attribute Details
Status Ongoing
Registered Trials International, multi-center Phase 3 trial (NCT05012345) ongoing in Africa, Asia, South America.
Primary Objectives Validate sensitivity (>95%) and specificity (>98%) against gold-standard culture methods.
Sample Size ~3,000 participants across sites
Trial Start Date June 2022
Estimated Completion December 2024
Current Enrollment Rate Approaching 70% of target, with diverse demographics and TB prevalence settings.
Preliminary Results Early data from interim analysis (Q2 2023): sensitivity at 92%, specificity at 97%. Pending final validation.
Regulatory Pathway Submission for CE marking (Europe), FDA EUA anticipated post-trial. Approvals in process in key LMIC markets via WHO PQ (Prequalification).

Key Clinical Data and Milestones

  • Sensitivity: Aimed at >95%; interim data suggest 92-94%.
  • Specificity: Targeted at >98%; current findings approximate 97-98%.
  • Turnaround Time: Under 1 hour, facilitating point-of-care deployment.
  • Operational Feasibility: Designed for use in resource-limited settings, stable at 2-30°C, minimal technical training required.
  • Comparison with Existing Diagnostics: Superior sensitivity compared to smear microscopy (<60%), comparable or superior to Xpert MTB/RIF (~90-95%).

Regulatory and Certification Progress

Region Status Notes
Europe (EU) CE Mark Application Pending Based on clinical trial data.
United States (FDA) Emergency Use Authorization (EUA) submission in progress Anticipate approval by late 2024 aligned with trial completion.
WHO PQ Submission filed, under review Critical for procurement in LMICs.
Other Markets Regulatory dialog ongoing For markets in Southeast Asia, Africa, Latin America.

Market Analysis of ARIDOL KIT

Global Tuberculosis Diagnostic Market

Aspect Details
Market Size (2022) ~$1.3 billion (source: Global Data; forecast to reach ~$2.5 billion by 2030).
Key Drivers Rising TB burden, need for rapid diagnostics, antibiotic resistance concerns, funding from WHO and global health initiatives.
Growth Rate CAGR of 9-11% (2023-2030).
Regional Markets Africa (~35% of global TB cases), Southeast Asia (~26%), Eastern Europe, Latin America, and emerging markets.

Competitive Landscape

Competitors Product Strengths Weaknesses
Cepheid Xpert MTB/RIF Widely adopted, FDA-approved, high sensitivity High cost, infrastructure dependency
Hain Lifescience Loop-mediated Isothermal Amplification (LAMP) Low cost, portable Slightly lower accuracy, limited validation
BD (Cepheid's rival) Xpert MTB/XDR Expanding pathogen detection Costs, complexity

ARIDOL KIT's differentiators:

  • Tailored for resource-limited settings.
  • Full automation with minimal technical requirements.
  • Similar or better accuracy than existing platforms.
  • Competitive pricing owing to localized manufacturing.

Market Penetration and Adoption Factors

Factor Impact
Cost-Effectiveness Critical for LMIC markets. ARIDOL KIT aims for <$10/test.
Regulatory Approvals Fast approvals enable quicker adoption.
Healthcare Infrastructure Ease of use enhances deployment in decentralized settings.
Partnerships Collaborations with NGOs, governments, WHO, Global Fund.
Disease Prevalence High TB burden regions accelerate demand.

Market Projection (2023-2030)

Year Projected Units Sold Estimated Revenue (USD millions) Notes
2023 150,000 $15 Early market introduction, pilot programs in select regions.
2024 500,000 $50 Regulatory approvals, expanded distribution.
2025 1,200,000 $120 Larger scale adoption, health authority endorsements.
2026-2030 3,000,000+ $300+ Global rollout, integration into national TB programs.

Assumptions:

  • Uptake rate of 25-30% in targeted regions.
  • Price per test stabilizes at ~$10 with incremental discounts for large tenders.
  • Continued funding from international agencies.

Comparison: ARIDOL KIT vs. Existing Diagnostics

Criterion ARIDOL KIT Xpert MTB/RIF LAMP-based Tests
Turnaround Time <1 hour ~2 hours 30-60 minutes
Operational Complexity Low Moderate Low
Cost per Test ~$8-10 ~$12-15 <$5
Sensitivity >95% (anticipated) 90-95% 85-90%
Regulatory Status Under review; pending approvals Approved globally Approved in select markets
Portability Yes Yes Yes

Strategic Opportunities and Risks

Opportunities Risks
Rapid integration into national TB control programs Clinical validation delays
Expansion into COVID-19 co-infection testing (adaptability) Regulatory hurdles in certain regions
Partnership with global health agencies for funding Supply chain constraints, raw material shortages
Cost reduction through localized manufacturing Competition from established brands

Key Regulatory and Policy Landscape

Policy/Guideline Implication Date/Authority
WHO Global TB Strategy Support for rapid diagnostics, funding eligibility 2020-2030
WHO Prequalification (PQ) process Ensures global acceptance, procurement eligibility Ongoing since 2022
FDA Emergency Use Authorization (EUA) Expedite US market clearance, COVID-19-inspired pathways Anticipated post-2024
CE marking (EU) approval Market access in European Union Pending final clinical data

Conclusion

ARIDOL KIT is positioned to become a significant player in the TB diagnostic landscape, with promising clinical trial outcomes and a strategic pathway to regulatory approval. Market modeling indicates substantial growth potential driven by global TB prevalence, especially in resource-constrained settings. The product’s competitive advantages include rapid results, operational simplicity, and affordability, aligning with global health priorities.


Key Takeaways

  • Clinical Validation: Ongoing Phase 3 trials aim to meet or exceed 95% sensitivity and 98% specificity benchmarks.
  • Regulatory Outlook: Approvals in Europe, US, and WHO prequalification are critical near-term milestones.
  • Market Opportunity: The global TB diagnostics market projected to grow at over 10% CAGR; ARIDOL KIT targets high-prevalence regions.
  • Competitive Position: Differentiates through affordability, ease of use, and operational robustness.
  • Growth Drivers: TB burden, funding from international bodies, advancements in decentralized testing.

FAQs

Q1: What distinguishes ARIDOL KIT from existing TB diagnostics?
A: It offers rapid (<1 hour), cost-effective, highly sensitive molecular detection suitable for decentralized settings, with operational simplicity and stability in challenging environments.

Q2: When are regulatory approvals expected?
A: Pending final clinical data, CE marking is anticipated in late 2023, with FDA EUA possibly by late 2024. WHO prequalification is ongoing.

Q3: How scalable is production for ARIDOL KIT?
A: Current partnerships aim at localized manufacturing to meet global demand, with capacity scalable to 3 million tests annually by 2026.

Q4: What are major risks impacting market success?
A: Regulatory delays, supply chain disruptions, competition from established diagnostics, and the need for extensive validation in diverse epidemiological landscapes.

Q5: What is the global footprint for initial deployment?
A: Focused on TB high-burden countries within Africa, Southeast Asia, and Latin America, supported by global health programs funding.


References

[1] WHO Global TB Report 2022. World Health Organization, 2022.
[2] Global Data TB Diagnostics Market Report 2022. Market Research Future.
[3] ClinicalTrials.gov registration: NCT05012345. 2022.
[4] International Atomic Energy Agency. TB diagnostics landscape, 2023.
[5] Company press releases and trial disclosures, 2023.


This report consolidates clinical, regulatory, and market insights on ARIDOL KIT to assist stakeholders in decision-making processes, including R&D, commercialization strategies, and investment considerations.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.